PHAT · Phathom Pharmaceuticals, Inc.

Track PHAT — free

$8.36 -0.01 (-0.12%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$676.33M

80.90M

Up next

Next earnings call

Oct 26, 2026 Est · unconfirmed · in 6 wks

Latest filing: 10-Q

filed Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$239.66M

Trailing 12 months

Net income (TTM)

−$99.07M

Trailing 12 months

Revenue growth YoY

+88.0%

Year over year

Operating margin

-17.0%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-5.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$17.89M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+15.6%

Year over year · more shares

Price change (1Y)

-30.7%

Trailing year

Short interest

13.4%

Latest settlement · 11.0 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −30%

below

Price vs 50-day avg −15%

below

RSI (14) 38

neutral

MACD trend Negative

52-week position 1%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −9%

trailing

6-month return −25%

trailing

YTD return −50%

this year

Relative strength −43%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $10 › 200d $12 — 200d above 50d

Institutional flow Distributing

-7% holders QoQ · +21 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

13.38% of float · ▼ -8.1% MoM · 11.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

163 holders — mid 3-yr range

Squeeze score 74

high risk · 0–100

Fundamentals

Strong

Revenue growth +217%

Y/Y

Gross margin 87%

expanding

EPS growth +43%

Y/Y

Free cash flow $-167.0M

Balance sheet $79.1M

net debt

Quant / Vol

risk profile

Very High

Volatility 64%

annualized · 1-yr

Max drawdown −54%

past year

ATR 6.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Jun 30, 2026

Revenue outlook · full year 2026 Initiated $310M – $325M

prior FY $175.11M midpoint +81.3% Y/Y

Gross-to-net discount · full year 2026 Initiated 55% – 59%

Gross margin · full year 2026 Initiated 80%

Cash operating expenses, excluding stock-based compensation · full year 2026 Non-GAAP Initiated $235M – $245M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−30% Bearish

Price vs 50-day avg

−15% Bearish

RSI (14)

38 Neutral

MACD trend

Negative Bearish

52-week position

1% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $10 › 200d $12 — 200d above 50d

Institutional flow Distributing

-7% holders QoQ · +21 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

13.38% of float · ▼ -8.1% MoM · 11.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

163 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $8 Now $8 · 1% Range high $18

vs 200-day avg -30% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PHAT Phathom Pharmaceuticals, Inc. this stock	$676.33M	-49.6%	+216.9%	—	13.4%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.64B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$80.46B	+1.2%	+20.8%	19.4	2.5%
ARGX Argenx SE	$61.22B	+17.1%	—	—	2.0%
MRNA Moderna, Inc.	$57.48B	+388.2%	+4.3%	—	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

163

% held: 90.4%
Net QoQ: +3.1M sh
Top holder: Frazier Life Sciences Man…

Held Float

View

Held by Funds

Fund positions

167

View

Short & Settlement

Short Interest Falling

Shares short

10.8M

Days to cover: 11.0d
Change: -950.0K sh

View

Short Volume

Short vol %

50%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

102.6K

Value: $941.2K
As of: Aug 13, 2026

View

Off-Exchange

Off-exchange %

45.1%

Week of: Aug 3, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$175.1M

Net income (FY): $-221.2M
EPS diluted: $-3.03

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 30, 2026
This year: 14

View

Earnings & Events

Earnings Calls

Last call

Jul 30, 2026

View

Performance

	5D	20D	120D	MTD	YTD
PHAT	-7.6%	-8.9%	-25.4%	-12.6%	-49.6%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-6.5%	-7.2%	-43.3%	-12.3%	-61.7%

Key facts CIK 1783183 CUSIP 71722W107 13F (30d) 64 filings 64 filers Visit website Investor relations

PHAT · Phathom Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance